McMinn Rachel 4
4 · Neurogene Inc. · Filed Feb 24, 2026
Insider Transaction Report
Form 4
Neurogene Inc.NGNE
McMinn Rachel
DirectorChief Executive Officer
Transactions
- Award
Common Stock
[F1][F2]2026-02-20+25,900→ 1,347,659 total - Award
Stock Option (Right to Buy)
[F3]2026-02-20+155,100→ 155,100 totalExercise: $17.64Exp: 2036-02-20→ Common Stock (155,100 underlying)
Footnotes (3)
- [F1]Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
- [F2]Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024. This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person.
- [F3]This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Signature
/s/ Donna M. Cochener, as attorney-in-fact for Rachel McMinn|2026-02-24